Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice

Figure 3

ML-1 containing drugs induce cell death in PBMCs and reduce their lytic activity. PBMCs were treated with ISCADOR Qu (ISC Qu), Aviscumine (Avi), or native ML-1 for 24 h or 48 h. (a) Cell viability of PBMCs was measured using MTT. (b–e) FACS analysis of activated T-cells treated for 48 h with ISCADOR Qu (ISC Qu) or Aviscumine (Avi). CD25 (b) and HLA-DR (c) surface expression. Cell death was measured by PI staining (d) and breakdown of the phospholipid asymmetry of the plasma membrane by AnnexinV binding (e). (f-g) Glioma cell lysis: Activated T-cells were left untreated (Ctrl) or were treated for 24 h with 2.4 ng/ml ISCADOR Qu (f) or Aviscumine (g). Afterwards these cells were cocultured for 4 h at different effector to target (E:T) ratios with LNT-229-Luc-cells. The remaining luciferase activity was measured and used to calculate the amount of glioma cell lysis (means ± SD, n=3; Student’s t-test compared to control < 0.05, < 0.01, < 0.001 after Bonferroni correction for n pair comparisons).

(a)

(b)

(c)

(d)

(e)

(f)

(g)